Skip to main content
. 2019 Dec 5;2019(12):CD011260. doi: 10.1002/14651858.CD011260.pub2

Comparison 1. IPV‐OPV versus OPV.

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
1 Persons with P1 Protective humoral response 12 3189 Risk Ratio (M‐H, Random, 95% CI) 1.00 [0.99, 1.01]
2 Persons with P1 Protective humoral response by time of first dose 12 3189 Risk Ratio (M‐H, Random, 95% CI) 1.00 [0.99, 1.01]
2.1 First dose at birth 1 50 Risk Ratio (M‐H, Random, 95% CI) 1.04 [0.91, 1.20]
2.2 First dose at 2 month 11 3139 Risk Ratio (M‐H, Random, 95% CI) 1.00 [0.99, 1.01]
3 Persons with P1 Protective humoral response by type of dose sequence 12 3189 Risk Ratio (M‐H, Random, 95% CI) 1.00 [0.99, 1.01]
3.1 Sequential IOO/IOOO 5 695 Risk Ratio (M‐H, Random, 95% CI) 1.00 [0.98, 1.01]
3.2 Sequential IIO/IIOO/IIIO 8 1772 Risk Ratio (M‐H, Random, 95% CI) 1.00 [0.99, 1.01]
3.3 Sequential IOI 2 722 Risk Ratio (M‐H, Random, 95% CI) 1.03 [0.93, 1.14]
4 Persons with P1 Protective humoral response by countries' income 12 3189 Risk Ratio (M‐H, Random, 95% CI) 1.00 [0.99, 1.01]
4.1 LMIC 4 1331 Risk Ratio (M‐H, Random, 95% CI) 1.00 [0.99, 1.01]
4.2 HIC 8 1858 Risk Ratio (M‐H, Random, 95% CI) 1.01 [0.99, 1.02]
5 Persons with P2 Protective humoral response 12   Risk Ratio (M‐H, Random, 95% CI) Subtotals only
5.1 IPV‐tOPV 11 2361 Risk Ratio (M‐H, Random, 95% CI) 1.00 [0.99, 1.01]
5.2 IIbO 1 105 Risk Ratio (M‐H, Random, 95% CI) 1.0 [0.93, 1.07]
5.3 IbObO vs tOPV 2 411 Risk Ratio (M‐H, Random, 95% CI) 0.78 [0.64, 0.96]
5.4 IbObO vs bOPV 1 306 Risk Ratio (M‐H, Random, 95% CI) 5.80 [4.06, 8.27]
6 Persons with P2 Protective humoral response by time of first dose 12 3186 Risk Ratio (M‐H, Random, 95% CI) 1.02 [0.98, 1.06]
6.1 First dose at birth 1 50 Risk Ratio (M‐H, Random, 95% CI) 1.05 [0.87, 1.26]
6.2 First dose at 2 month 11 3136 Risk Ratio (M‐H, Random, 95% CI) 1.02 [0.98, 1.06]
7 Persons with P2 Protective humoral response by type of dose sequence 12   Risk Ratio (M‐H, Random, 95% CI) Subtotals only
7.1 Sequential IbObO (bOPV) 1 211 Risk Ratio (M‐H, Random, 95% CI) 0.85 [0.78, 0.91]
7.2 Sequential IOO/IOOO 4 484 Risk Ratio (M‐H, Random, 95% CI) 1.00 [0.98, 1.02]
7.3 Sequential IIO/IIOO/IIIO 8 1768 Risk Ratio (M‐H, Random, 95% CI) 1.00 [0.99, 1.01]
7.4 Sequential IbOI (vs bObObO) 1 305 Risk Ratio (M‐H, Random, 95% CI) 5.85 [4.10, 8.34]
7.5 Sequential IbOI 1 309 Risk Ratio (M‐H, Random, 95% CI) 0.82 [0.75, 0.90]
7.6 Sequential IOI 1 109 Risk Ratio (M‐H, Random, 95% CI) 1.08 [0.99, 1.17]
8 Persons with P2 Protective humoral response by countries' income 12 3186 Risk Ratio (M‐H, Random, 95% CI) 1.02 [0.98, 1.06]
8.1 LMIC 4 1331 Risk Ratio (M‐H, Random, 95% CI) 0.98 [0.96, 1.01]
8.2 HIC 8 1855 Risk Ratio (M‐H, Random, 95% CI) 1.06 [0.96, 1.17]
9 Persons with P3 Protective humoral response 12 3184 Risk Ratio (M‐H, Random, 95% CI) 0.99 [0.97, 1.00]
10 Persons with P3 Protective humoral response by time of first dose 12 3013 Risk Ratio (M‐H, Random, 95% CI) 0.99 [0.97, 1.01]
10.1 Fist dose at birth 1 50 Risk Ratio (M‐H, Random, 95% CI) 1.17 [0.87, 1.57]
10.2 First dose at 2 month 11 2963 Risk Ratio (M‐H, Random, 95% CI) 0.99 [0.97, 1.01]
11 Persons with P3 Protective humoral response by type of dose sequence 12 3184 Risk Ratio (M‐H, Random, 95% CI) 0.98 [0.96, 1.00]
11.1 Sequential IbObO 1 105 Risk Ratio (M‐H, Random, 95% CI) 0.70 [0.60, 0.82]
11.2 Sequential IOO/IOOO 5 590 Risk Ratio (M‐H, Random, 95% CI) 0.98 [0.96, 1.00]
11.3 Sequential IIO/IIOO/IIIO 8 1767 Risk Ratio (M‐H, Random, 95% CI) 0.99 [0.96, 1.01]
11.4 Sequential IOI 2 722 Risk Ratio (M‐H, Random, 95% CI) 0.99 [0.95, 1.03]
12 Persons with P3 Protective humoral response by countries' income 12 3013 Risk Ratio (M‐H, Random, 95% CI) 0.99 [0.97, 1.01]
12.1 LMIC 4 1159 Risk Ratio (M‐H, Random, 95% CI) 0.99 [0.98, 1.01]
12.2 HIC 8 1854 Risk Ratio (M‐H, Random, 95% CI) 0.98 [0.94, 1.01]
13 Mean titres of P1 neutralising antibody 6   Mean Difference (IV, Random, 95% CI) Subtotals only
13.1 Sequential IbObO 1 125 Mean Difference (IV, Random, 95% CI) 362.12 [‐329.70, 1053.94]
13.2 Sequential IOO 3 606 Mean Difference (IV, Random, 95% CI) ‐181.13 [‐594.25, 231.99]
13.3 Sequential IIO 3 795 Mean Difference (IV, Random, 95% CI) ‐244.37 [‐827.31, 338.57]
13.4 Sequential IIIOO/IIIO 2 551 Mean Difference (IV, Random, 95% CI) 439.07 [‐354.63, 1232.77]
14 Mean titres of P2 neutralising antibody 6   Mean Difference (IV, Random, 95% CI) Subtotals only
14.1 Sequential IbObO 1 125 Mean Difference (IV, Random, 95% CI) ‐260.38 [‐347.21, ‐173.55]
14.2 Sequential IOO 3 606 Mean Difference (IV, Random, 95% CI) 28.64 [‐22.16, 79.43]
14.3 Sequential IIbO 1 125 Mean Difference (IV, Random, 95% CI) ‐217.90 [‐305.36, ‐130.44]
14.4 Sequential IIO 3 667 Mean Difference (IV, Random, 95% CI) 267.40 [‐83.95, 618.76]
14.5 Sequential IIIOO/IIIO 2 551 Mean Difference (IV, Random, 95% CI) 486.17 [‐698.02, 1670.37]
15 Mean titres of P3 neutralising antibody 6   Mean Difference (IV, Random, 95% CI) Subtotals only
15.1 Sequential IbObO 1 125 Mean Difference (IV, Random, 95% CI) 221.03 [9.66, 432.40]
15.2 Sequential IOO 3 606 Mean Difference (IV, Random, 95% CI) 44.07 [‐1.47, 89.61]
15.3 Sequential IIbO 1 125 Mean Difference (IV, Random, 95% CI) 591.78 [185.14, 998.42]
15.4 Sequential IIO 3 667 Mean Difference (IV, Random, 95% CI) 89.97 [8.98, 170.97]
15.5 Sequential IIIOO/IIIO 2 551 Mean Difference (IV, Random, 95% CI) 248.39 [‐180.58, 677.37]
16 Long term mean titres of P1 neutralising antibody 1 86 Mean Difference (IV, Random, 95% CI) 0.35 [0.07, 0.63]
16.1 Sequential IOO 1 20 Mean Difference (IV, Random, 95% CI) 0.0 [‐0.48, 0.48]
16.2 Sequential IOO+O 1 20 Mean Difference (IV, Random, 95% CI) 0.20 [‐0.33, 0.73]
16.3 Sequential IIO 1 23 Mean Difference (IV, Random, 95% CI) 0.60 [0.22, 0.98]
16.4 Sequential IIO+O 1 23 Mean Difference (IV, Random, 95% CI) 0.5 [0.01, 0.99]
17 Long term mean titres of P2 neutralising antibody 1 86 Mean Difference (IV, Random, 95% CI) 0.12 [‐0.07, 0.31]
17.1 Sequential IOO 1 20 Mean Difference (IV, Random, 95% CI) 0.10 [‐0.26, 0.46]
17.2 Sequential IOO+O 1 20 Mean Difference (IV, Random, 95% CI) 0.10 [‐0.30, 0.50]
17.3 Sequential IIO 1 23 Mean Difference (IV, Random, 95% CI) 0.0 [‐0.38, 0.38]
17.4 Sequential IIO+O 1 23 Mean Difference (IV, Random, 95% CI) 0.30 [‐0.11, 0.71]
18 Long term mean titres of P3 neutralising antibody 1 86 Mean Difference (IV, Random, 95% CI) 0.08 [‐0.29, 0.45]
18.1 Sequential IOO 1 20 Mean Difference (IV, Random, 95% CI) ‐0.50 [‐1.14, 0.14]
18.2 Sequential IOO+O 1 20 Mean Difference (IV, Random, 95% CI) 0.0 [‐0.61, 0.61]
18.3 Sequential IIO 1 23 Mean Difference (IV, Random, 95% CI) 0.40 [0.02, 0.78]
18.4 Sequential IIO+O 1 23 Mean Difference (IV, Random, 95% CI) 0.20 [‐0.34, 0.74]
19 Persons with polio faecal excretion after OPV challenge 2   Risk Ratio (M‐H, Random, 95% CI) Subtotals only
19.1 Persons with P1 faecal excretion 2 916 Risk Ratio (M‐H, Random, 95% CI) 2.24 [0.70, 7.12]
19.2 Persons with P2 faecal excretion 2 916 Risk Ratio (M‐H, Random, 95% CI) 1.78 [1.49, 2.14]
19.3 Persons with P3 faecal excretion 2 916 Risk Ratio (M‐H, Random, 95% CI) 2.35 [1.47, 3.76]
20 Vaccination coverage 1   Risk Ratio (Random, 95% CI) 1.01 [0.96, 1.06]
21 Serious adverse events classified by MedDRA 4 1948 Risk Ratio (M‐H, Random, 95% CI) 0.88 [0.46, 1.70]